What NeuroSense Therapeutics Ltd.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 2 |
| Sells | 0 | 0 |
| Total trades | 2 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 5 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Eisenberg Or | Chief Financial Officer | Jun 16 | Open-market buy · P | +250,000 | $0.80 | +$200K | 1,504,050 |
| Ben-Noon Alon | Chief Executive Officer | Jun 16 | Open-market buy · P | +250,000 | $0.80 | +$200K | 4,534,233 |
| Russek-Blum Niva | Chief Technology Officer | Mar 26 | Grant / award · A | +200,000 | — | — | 467,953 |
| Eisenberg Or | Chief Financial Officer | Mar 26 | Grant / award · A | +200,000 | — | — | 1,254,050 |
| Binder Hagit | General Manager | Mar 26 | Grant / award · A | +200,000 | — | — | 521,806 |
Loading...
